(0.25%) 5 321.41 points
(0.17%) 39 873 points
(0.22%) 16 833 points
(-0.25%) $79.06
(-1.65%) $2.63
(-0.09%) $2 423.70
(0.27%) $32.17
(0.00%) $1 060.90
(0.01%) $0.921
(0.00%) $10.66
(-0.05%) $0.786
(0.33%) $90.53
Live Chart Being Loaded With Signals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...
Stats | |
---|---|
今日成交量 | 30 843.00 |
平均成交量 | 130 072 |
市值 | 90.38M |
EPS | $0 ( 2024-05-14 ) |
下一个收益日期 | ( $-0.770 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0400 |
ATR14 | $0.0580 (0.45%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Amoroso Michael | Buy | 8 334 | Common Stock |
2024-05-08 | Kelly John Alexander | Buy | 8 334 | Common Stock |
2024-05-08 | Smith J. Jefferson | Buy | 833 | Common Stock |
2024-05-08 | Scimeca Dario | Buy | 833 | Common Stock |
2024-05-04 | Pire Shari Lisa | Buy | 4 202 | Common Stock |
INSIDER POWER |
---|
14.39 |
Last 100 transactions |
Buy: 2 573 781 | Sell: 1 742 339 |
音量 相关性
Precision BioSciences Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Precision BioSciences Inc 相关性 - 货币/商品
Precision BioSciences Inc 财务报表
Annual | 2023 |
营收: | $48.73M |
毛利润: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2023 |
营收: | $48.73M |
毛利润: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2022 |
营收: | $25.10M |
毛利润: | $16.09M (64.12 %) |
EPS: | $-41.95 |
FY | 2021 |
营收: | $115.53M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。